Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Ramaswamy Govindan, Bob T. Li et al.|New England Journal of Medicine|2021Cited by 1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, José Baselga, Antoîne Italiano et al.|New England Journal of Medicine|2015Cited by 1.7k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Shreyaskumar Patel, Sant P. Chawla et al.|The Lancet|2016Cited by 766
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Jean‐Charles Soria et al.|The Lancet Oncology|2018Cited by 614
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II TrialSophie Cousin, Antoîne Italiano|Clinical Cancer Research|2021Cited by 152